Journal of Biological Chemistry · 2015 · 329 citations · 38 references
Life SciencesImmunologyPharmacologyCell SignalingInflammationInnate ImmunityInflammatory SignalingInnate Immune ModulationMacrophage BiologyMetabolic InflammationReactive Oxygen SpeciesRedox SignalingMacrophage ImmunomodulationMacrophage Oxidative StressMacrophage Reactive Oxygen Species ResponsesOxidoreductase EnzymesReactive Oxygen Species GenerationReactive Oxygen Species RegulationReactive Oxygen Species Signaling
Metformin, a frontline treatment for type II diabetes mellitus, decreases production of the pro-form of the inflammatory cytokine IL-1β in response to LPS in macrophages. We found that it specifically inhibited pro-IL-1β production, having no effect on TNF-α. Furthermore, metformin boosted induction of the anti-inflammatory cytokine IL-10 in response to LPS. We ruled out a role for AMP-activated protein kinase (AMPK) in the effect of metformin because activation of AMPK with A769662 did not mimic metformin here. Furthermore, metformin was still inhibitory in AMKPα1- or AMPKβ1-deficient cells. The activity of NADH:ubiquinone oxidoreductase (complex I) was inhibited by metformin. Another complex I inhibitor, rotenone, mimicked the effect of metformin on pro-IL-1β and IL-10. LPS induced reactive oxygen species production, an effect inhibited by metformin or rotenone pretreatment. MitoQ, a mitochondrially targeted antioxidant, decreased LPS-induced IL-1β without affecting TNF-α. These results, therefore, implicate complex I in LPS action in macrophages. Metformin, a frontline treatment for type II diabetes mellitus, decreases production of the pro-form of the inflammatory cytokine IL-1β in response to LPS in macrophages. We found that it specifically inhibited pro-IL-1β production, having no effect on TNF-α. Furthermore, metformin boosted induction of the anti-inflammatory cytokine IL-10 in response to LPS. We ruled out a role for AMP-activated protein kinase (AMPK) in the effect of metformin because activation of AMPK with A769662 did not mimic metformin here. Furthermore, metformin was still inhibitory in AMKPα1- or AMPKβ1-deficient cells. The activity of NADH:ubiquinone oxidoreductase (complex I) was inhibited by metformin. Another complex I inhibitor, rotenone, mimicked the effect of metformin on pro-IL-1β and IL-10. LPS induced reactive oxygen species production, an effect inhibited by metformin or rotenone pretreatment. MitoQ, a mitochondrially targeted antioxidant, decreased LPS-induced IL-1β without affecting TNF-α. These results, therefore, implicate complex I in LPS action in macrophages.
38
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
PubMed · 1997 · 66.6K citations
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou, Robert P. Myers, Ying Li et al. · Journal of Clinical Investigation · 2001 · 5.4K citations
A central role for JNK in obesity and insulin resistance
Jiro Hirosumi, Gürol Tuncman, Lufen Chang et al. · Nature · 2002 · 3.3K citations
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
Claus M. Larsen, Mirjam Faulenbach, Allan Vaag et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text